1. Scrip
  2. >>Business

Interview: Setting The Course For Takeda’s R&D Future

 
• By Ian Haydock

Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company's chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 18 months.

In the first of this two-part interview, conducted at Takeda Pharmaceutical Co. Ltd.'s headquarters in Tokyo during one of his regular visits to Japan, Plump outlines the strategic thinking behind Takeda's recent R&D reorganization and its decision to focus on selected therapeutic areas.

For Part 2 ([A#sc099084])

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Rocket Comes Back To Earth With Restructuring Plan

 
• By Alaric DeArment

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.